SeekingAlpha · Oct 28, 2026
Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
Explore why Nautilus could be a long-term proteomics stock, with oncology expansion, research collaborations, and runway to launch Voyager.
NA
NASDAQ · NAUT
Nautilus Biotechnology, Inc.
Healthcare · Biotechnology
$2.35
Up+$0.02 (+0.64%)
Updated Nov 4, 2026, 4:48 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 250.72M
- P/E ratio
- -3.99
- Dividend yield
- 0.00%
- 52-week range
- $0.84 – $4.31
- Volume
- 4.8M
- Avg. volume
- 507.75K
Price performance · NAUT
NAUT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
NAUT closed at $2.35 after 21 trading sessions, up 32.77% for the selected period.
- Last close
- $2.35
- Period change
- +32.77%
- Period low
- $1.77
- Period high
- $3.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.40 | $2.55 | $2.315 | $2.35 | 4.8M |
| Nov 2, 2026 | $2.74 | $2.7545 | $2.27 | $2.335 | 7.31M |
| Oct 30, 2026 | $2.88 | $3.08 | $2.64 | $2.73 | 8.07M |
| Oct 29, 2026 | $3.22 | $3.42 | $3.08 | $3.14 | 7.51M |
| Oct 28, 2026 | $3.00 | $3.34 | $2.80 | $3.21 | 15.15M |
| Oct 27, 2026 | $2.34 | $3.02 | $2.1714 | $2.89 | 20.7M |
| Oct 26, 2026 | $3.145 | $3.18 | $2.23 | $2.44 | 16.59M |
| Oct 23, 2026 | $2.58 | $3.26 | $2.57 | $3.24 | 13.79M |
| Oct 22, 2026 | $2.72 | $2.86 | $2.535 | $2.60 | 6.91M |
| Oct 21, 2026 | $2.50 | $2.83 | $2.50 | $2.71 | 8.66M |
| Oct 20, 2026 | $2.615 | $2.71 | $2.38 | $2.55 | 10.02M |
| Oct 19, 2026 | $2.03 | $2.68 | $1.97 | $2.63 | 14.97M |
| Oct 16, 2026 | $2.17 | $2.2299 | $1.99 | $2.06 | 6.46M |
| Oct 15, 2026 | $2.07 | $2.20 | $1.88 | $2.16 | 8.64M |
| Oct 14, 2026 | $2.00 | $2.1899 | $1.91 | $2.16 | 8.18M |
| Oct 13, 2026 | $2.125 | $2.34 | $2.00 | $2.05 | 7.47M |
| Oct 12, 2026 | $2.165 | $2.25 | $1.8601 | $2.17 | 13.55M |
| Oct 9, 2026 | $1.93 | $2.46 | $1.85 | $2.25 | 19.58M |
| Oct 8, 2026 | $2.00 | $2.01 | $1.75 | $1.82 | 6.61M |
| Oct 7, 2026 | $1.67 | $2.17 | $1.62 | $1.96 | 12.53M |
| Oct 6, 2026 | $1.89 | $2.09 | $1.725 | $1.77 | 11.02M |
Latest NAUT news
The latest Smart Investors Daily articles mentioning NAUT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NAUT research
Overview
Company profile and research snapshot.
Company profile
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Roth Capital | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Feb 27, 2026 | Guggenheim | Buy | — |
| Dec 5, 2024 | Goldman Sachs | Sell | — |
| Jun 27, 2024 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Nautilus Biotechnology, Inc. Q3 2026 Earnings Call Summary
Moby summary of Nautilus Biotechnology, Inc.'s Q3 2026 earnings call
Yahoo · Oct 27, 2026
Nautilus (NAUT) Q3 2026 Earnings Call Transcript
Cash reserves extend runway into early 2028 as proteoform assay pipeline accelerates.
Yahoo · Oct 27, 2026
Nautilus Biotechnology Q3 Earnings Call Highlights
Nautilus Biotechnology (NASDAQ:NAUT) reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking platform pre-orders in early 2027 and start instrument shipments in mid-2027.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
